Here's some of what is coming soon to NeurologyLive® this week.
News|Articles|July 3, 2025
FDA Action Update, June 2025: Approval, Acceptance, Expanded Indication
Author(s)Isabella Ciccone, MPH
Catch up on any of the neurology news headlines you may have missed over the course of June 2025, compiled all into one place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy in June 2025, making a number of decisions on potential new therapeutic agents including granting an approval, accepting a new drug application, and greenlighting an expanded indication.
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.
Advertisement
Advertisement